Literature DB >> 27420116

Reversing Cancer Multidrug Resistance in Xenograft Models via Orchestrating Multiple Actions of Functional Mesoporous Silica Nanoparticles.

Debin Yang1, Tingfang Wang1, Zhigui Su1, Lingjing Xue1, Ran Mo1, Can Zhang1.   

Abstract

A multistimuli responsive drug delivery system (DDS) based on sulfhydryl and amino-cofunctionalized mesoporous silica nanoparticles (SH/NH2-MSNs) has been developed, in which the multifunctional hyaluronic acid (HA) derivatives were grafted onto the SH/NH2-MSNs by disulfide bonds for targeting delivery, controlling drug release and reversing multidrug resistance (MDR). The doxorubicin (Dox) loaded multifunctional HA derivatives modified mesoporous silica nanoparticles (Dox/HHS-MSNs) were enzyme and redox sensitive, which could respond to the intracellular stimuli of hyaluronidase (HAase) and glutathione (GSH) successively and prevent drug leakage before reaching the tumor tissues. The cellular uptake experiments showed that Dox/HHS-MSNs were vulnerable to be endocytosed into the Dox-resistant human breast adenocarcinoma (MCF-7/ADR) cells, efficiently realized the endolysosomal escape and remained in the cytoplasm. Because of orchestrating multiple actions above including active targeting, endolysosomal escape and efficient multilevel drug release, Dox/HHS-MSNs could induce the strongest apoptosis and cytotoxicity of MCF-7/ADR cells. Furthermore, a series of in vivo studies on MCF-7/ADR tumor-bearing xenograft mouse models demonstrated that Dox/HHS-MSNs possessed the enhanced tumor-targeting capacity and the best therapeutic efficacy to reverse cancer MDR.

Entities:  

Keywords:  active targeting; endolysosomal escape; enzyme and redox sensitive; mesoporous silica nanoparticles; multidrug resistance; multilevel drug release

Year:  2016        PMID: 27420116     DOI: 10.1021/acsami.6b04885

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  7 in total

1.  Cascade-Targeting of Charge-Reversal and Disulfide Bonds Shielding for Efficient DOX Delivery of Multistage Sensitive MSNs-COS-SS-CMC.

Authors:  Lan Cui; Wentao Liu; Hao Liu; Qian Qin; Shuangxia Wu; Suqin He; Zhenya Zhang; Xinchang Pang; Chengshen Zhu
Journal:  Int J Nanomedicine       Date:  2020-08-17

Review 2.  Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Authors:  Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2019-04-22       Impact factor: 6.648

Review 3.  Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.

Authors:  Ranjith Kumar Kankala; Ya-Hui Han; Hong-Ying Xia; Shi-Bin Wang; Ai-Zheng Chen
Journal:  J Nanobiotechnology       Date:  2022-03-12       Impact factor: 10.435

4.  A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance.

Authors:  Jinjin Shi; Yu Su; Wei Liu; Junbiao Chang; Zhenzhong Zhang
Journal:  Int J Nanomedicine       Date:  2017-11-14

5.  Paclitaxel and quercetin nanoparticles co-loaded in microspheres to prolong retention time for pulmonary drug delivery.

Authors:  Kang Liu; Weijuan Chen; Tingting Yang; Baofang Wen; Dejun Ding; Michael Keidar; Jinbao Tang; Weifen Zhang
Journal:  Int J Nanomedicine       Date:  2017-11-13

6.  Sequential Delivery of Cyclopeptide RA-V and Doxorubicin for Combination Therapy on Resistant Tumor and In Situ Monitoring of Cytochrome c Release.

Authors:  Huachao Chen; Yurong Wang; Yongrong Yao; Shenglin Qiao; Hao Wang; Ninghua Tan
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

7.  Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance.

Authors:  Weihong Guo; Lizhi Deng; Jiang Yu; Zhaoyu Chen; Yanghee Woo; Hao Liu; Tuanjie Li; Tian Lin; Hao Chen; Mingli Zhao; Liming Zhang; Guoxin Li; Yanfeng Hu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.